Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session titled, “HPA axis modulation by a potent inhibitor indicates 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors” at the 24th European Congress of Endocrinology (ECE 2022).

Sparrow Pharmaceuticals today announced that the FDA has cleared an IND that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62 for the treatment of ACTH-dependent Cushing’s syndrome. The company also announced that it has expanded its clinical capabilities by hiring Kim Hunsicker as Head of Clinical Operations and Sarah Hooper as Clinical Project Manager.

Sparrow Pharmaceuticals announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality. Dr. Czerwiec has more than 35 years of experience in industry, academia, and public service, while Dr. MacPherson brings her more than 20 years of experience as a regulatory affairs and quality assurance professional in the pharmaceutical and biotechnology industries across a wide variety of therapeutic areas.

Sparrow Pharmaceuticals presented new data at the European Congress of Endocrinology 2021 on 22-26 May 2021 as a poster presentation, “SPI-62: An investigational HSD-1 inhibitor for the treatment of Cushing syndrome”.

Sparrow Pharmaceuticals announced the closing of a $50 million Series A financing. OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).